APPLICATION DEADLINE: WEDNESDAY, FEBRUARY 18
XLR8 PBC is designed for health tech companies that are prepared to scale (abaca 6). Ideal applicants have a validated product or solution, early traction in the market, and are seeking strategic partnerships, mentorship, and investor connections to accelerate their growth. The program lasts 6 months, with two in-person sessions in Phoenix. APPLYContinue reading
Six years after the COVID pandemic, the virtues of remote health care are clear: Allowing patients to visit with their providers via phone or video call often means better access to health care for patients, including those in rural communities and those who struggle to leave their homes.
But the laws that regulate telehealth, as it’s known, have not kept pace with its rise and demand – at least not in the form of comprehensive legislation. Since the pandemic, Congress has funded telehealth largely on a stopgap basis, temporarily extending COVID-era flexibilities more than a dozen times in the last few years. Each time, the extension provides only temporary funding to the Centers for Medicare and Medicaid Services – the nation’s largest funder of telehealth services.
The newest deadline for Congress to act on telehealth policy – the 15th deadline set on this issue since the COVID pandemic – is Jan. 30.Continue reading
Included is a dedicated polycystic kidney disease track alongside investments in brain health, pediatrics, and rare diseases.Continue reading
AdvaMed, the Medtech Association, announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.Continue reading
In 2003, The Marley Foundation stepped forward as an early partner of TGen, united by a shared commitment to advance early detection methods for life-threatening cancer diagnoses. Twenty years later they have advanced the “Marley equation” assisting in earlier detection of pancreatic cancer.Continue reading
Nutrition efforts, biomedical workforce, new medical school among the initiatives coveredContinue reading
Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership.Continue reading
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026Continue reading
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ — West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing conditions, is expected to close in mid-2026.
[Editors Note: West Pharma manufacturers the SmartDose® 3.5mL On-Body Delivery System at its facilities in Tempe, AZ.]
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management.Continue reading